Prestige Consumer Healthcare Raises FY27 Outlook to Include Acquisitions
PBH sits 24% above its 52-week low of $42.62.
Summary
Prestige Consumer Healthcare raised its fiscal 2027 outlook to include the impact of recent acquisitions, following the $1.045 billion Breathe Right deal closed in June and the $150 million LaCorium Health acquisition completed in July. The company now expects fiscal 2027 revenue of $1.29 billion to $1.32 billion and adjusted earnings per share of $4.55 to $4.65. The raised guidance signals management expects these deals to be accretive sooner than the market may have priced in. With the stock at $52.97 and a $2.5 billion market cap, the updated outlook could shift earnings estimates and valuation. The company has been active in M&A while managing a decline in organic revenue, making the integration and performance of these new assets critical.
Updates
· SEC 8-K — Q1 revenue was $265.7 million, up 6.5%, with adjusted diluted EPS of $0.98. Organic sales grew 3.2%. Adjusted free cash flow was $83.7 million. Net debt was about $2 billion at June 30.
At the time of this announcement, PBH was trading at $52.97 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $42.62 to $75.31. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.